LF:aVLFA0822p Pharmacology II - lec. - Course Information
aVLFA0822p Pharmacology II - lecture
Faculty of Medicinespring 2025
- Extent and Intensity
- 2/0/0. 3 credit(s). Type of Completion: zk (examination).
In-person direct teaching - Teacher(s)
- doc. MUDr. Regina Demlová, Ph.D. (lecturer)
doc. PharmDr. Jan Juřica, Ph.D. (lecturer)
Mgr. Petra Amchová, Ph.D. (lecturer)
doc. RNDr. Ladislava Bartošová, Ph.D. (lecturer)
Carlos Daniel Ferreira Fonseca, MSc. (lecturer)
PharmDr. Mária Hricková (lecturer)
Mgr. Jana Kubátová, Ph.D. (lecturer)
doc. Mgr. MVDr. Leoš Landa, Ph.D. (lecturer)
Mgr. Kristýna Nosková, Ph.D. (lecturer)
MUDr. Jana Nováková, Ph.D. (lecturer)
MUDr. Jana Pistovčáková, Ph.D. (lecturer)
doc. PharmDr. Jana Rudá, Ph.D. (lecturer)
PharmDr. Jitka Rychlíčková, Ph.D. (lecturer)
Mgr. Barbora Říhová, Ph.D. (lecturer)
PharmDr. Lenka Součková, Ph.D. (lecturer)
doc. PharmDr. Ondřej Zendulka, Ph.D. (lecturer)
MUDr. Róbert Balog (assistant)
Renata Bláblová (assistant)
PharmDr. Tomáš Hammer (assistant)
PharmDr. Eva Klásková (assistant)
MUDr. Filip Šiška (assistant)
PharmDr. Katarína Kostolanská (alternate examiner) - Guaranteed by
- doc. MUDr. Regina Demlová, Ph.D.
Department of Pharmacology – Theoretical Departments – Faculty of Medicine
Contact Person: doc. Mgr. MVDr. Leoš Landa, Ph.D.
Supplier department: Department of Pharmacology – Theoretical Departments – Faculty of Medicine - Prerequisites (in Czech)
- aVLFA0721p Pharmacology I - lecture && aVLPF0622p Pathophysiology II - lecture
- Course Enrolment Limitations
- The course is also offered to the students of the fields other than those the course is directly associated with.
- fields of study / plans the course is directly associated with
- General Medicine (programme LF, M-GM)
- General Medicine (eng.) (programme LF, M-VL)
- Course objectives
- The aim of the course is to acquiant the students with drugs from selected pharmacotherapeutic groups.
- Learning outcomes
- At the end of the course student should be able choose and prescribe suitable drug for the patient with known indicication. The selection will be made with respect to all factors influencing drug safety and efficacy.
- Syllabus
aVLFA0822p - Pharmacology II lecture
General medicine
Spring semester 2024
- (19.2. 2024)
- 1. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
- Lecture content: History and classification of psychotropic substances. Pharmacological review of antipsychotics and antiparkinsonics.
- (26.2. 2024)
- 2. ANTIDEPRESSANTS
- Lecture content: Pharmacological review of antidepressants and psychostimulants and their clinical use.
- (4.3. 2024)
- 3. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS
- Lecture content: Pharmacological review of anxiolytics, hypnosedatives, anticonvulsants. The possibilities of modulation of GABAergic neurotransmission and other central neurotransmitters. Self-study: drug dependence and its possible therapy.
- (11.3. 2024)
- 4. GENERAL AND LOCAL ANAESTHETICS
- Lecture content: Classification and basic features of general and local anaesthetic drugs. Review of drugs used in premedication and postanesthesia care.
- (18.3. 2024)
- 5. VASODILATORS AND DRUGS WITH EFFECT ON VESSELS
- Lecture content: Risk factors of cardiovascular diseases, lipid-lowering drugs, nitrates, donors of NO groups, calcium channel blockers and other groups of direct vasodilators.
- (25.3. 2024)
- 6. DRUGS INFLUENCING RAAS, DIURETICS
- Lecture content: Pharmacological profiles of drugs targeting RAAS and diuretics. Antagonists of mineralocorticoid receptors. Antihypertensives of the 1st and 2nd choice, combinations, central antihypertensives.
- (2.4. 2024)
- 7. DRUGS DIRECTLY INFLUENCING MYOCARDIUM
- Lecture content: Beta-blockers and bradins, drugs with positive inotropic effects. Calcium channel blockers- non-DHP, antiarrhythmics.
- (8.4. 2024)
- 8. DRUGS INFLUENCING HAEMOSTASIS
- Lecture content: Pharmacological profiles of anticoagulants, antiplatelet drugs, fibrinolytics, anti-fibrinolytics and haemostatics.
- (15.4. 2024)
- 9. ANTI-INFECTIVES I – ANTIBACTERIAL SUBSTANCES
- Lecture content: Introduction and basic principles of antimicrobial therapy. Modes of resistance to antimicrobial drugs. Pharmacological review of antibiotics.
- (22.4. 2024)
- 10. ANTI-INFECTIVES II – ANTIFUNGAL AND ANTIVIRAL DRUGS
- Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis.
- (29.4. 2024)
- 11. PHARMACOLOGY OF GIT – ANTIEMETICS, ANTIDIARRHEALS, LAXATIVES, THERAPY OF PEPTIC ULCER DISEASE AND IBD
- Lecture content: Pharmacological review of GIT drugs.
- (6.5. 2024)
- 12. CYTOSTATICS AND TARGETED THERAPY IN ONCOLOGY
- Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Main classes of cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
- (13.5. 2024)
- 13. THERAPY OF INTOXICATIONS
- Lecture content: Review of most common intoxications and their symptomatology. General principles of poisoning management. Specific antidotes in poisoning therapy.
- (20.5. 2024)
- 14. DRUG INTERACTIONS
- Lecture content: Classification of drug-drug interactions, evaluation of clinical relevance and seriousness of DDI. Monitoring of drug-drug interactions and their management.
- (27.5. 2024)
- 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
- Lecture content: Natural sources of medicines, selected groups of active constituents. Herbal preparations. Herbal poisons.
- Literature
- required literature
- RITTER, James, R. J. FLOWER, Graeme HENDERSON, Yoon Kong LOKE, David J. MACEWAN and H. P. RANG. Rang and Dale's pharmacology. Ninth edition. Edinburgh: Elsevier, 2020, xvi, 789. ISBN 9780702074486. info
- LANDA, Leoš, Jan JUŘICA, Kristýna NOSKOVÁ and Ondřej ZENDULKA. Selected chapters from general pharmacology for students of general medicine and dentistry at MF MU. Brno, 2020. info
- Study materials in the IS, course aVLFA0822p and aVLFA0822c
- Exam question outlines in the IS
- recommended literature
- WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015, xi, 664. ISBN 9781451191776. info
- Teaching methods
- video recordings of lectures in IS
- Assessment methods
- The final evaluation of the course contains also results of the tests from practicals of both semesters and results of colloquium test.
The final mark is calculated by following method:
Relative weight of the mark from tests: 30 %
Relative weight of the mark from oral exam: 70 %
To calculate mark from the tests the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. Minimum to pass through the course to the oral exam is 128 pts.
A = 210-230 pts
B = 190-209 pts
C = 160-189 pts
D = 140-159 pts
E = 128-139 pts
F = less than 128 pts
To calculate mark from the oral examthe following method will be used:
Three different questions are chosen by students from three different sets of questions at oral exam. Moreover the student answers additional questions of examinator. Drawn questions from General and Special pharmacology and the additional questions have relative weight of 30 %. The question on essential drugs has realtive weight 10 % in the final mark of the oral exam. When student is evaluated by F for any of these questions the overall rating of oral exam is also F.
In case of success with the ROPOT test, but classification F from the oral part, students enter the oral part next time and for the final mark the score from the last ROPOT attempt is used. - Language of instruction
- English
- Further comments (probably available only in Czech)
- The course is taught annually.
Information on the extent and intensity of the course: 30. - Listed among pre-requisites of other courses
- aVLAM9X1p Intensive Care Medicine - lecture
aVLFA0822p && aVLCH0832c && aVLDI7X1c && aVLOT7X1c - aVLCH11Xpp Surgery - pregraduation practice
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL101 && aVLIN9X22p && aVLON9X1p && aVLCH9X33c && aVLCH091 && aVLOZ1044 && aVLPD1033c && aVLCJ0888 && (aVLPG1022c ||aVLPG9X1) - aVLCH11XX Surgery - state exam
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL7X61c && aVLVL9X62c && aVLVL9X63c && aVLVL9X64c && aVLVL9X65c && aVLVL101 && aVLIN9X22p && aVLCH091 && aVLCH9X33c && aVLON9X1p && aVLOZ1044 && aVLPD1033c && VYCET(1,aVLAL091,aVLDO091,aVLAF091,aVLKB091,aVLFP091,aVLAP111) && aVLCH9X33c && aVLCJ0888 && aVLSP03X && (aVLPG1022c ||aVLPG9X1) && aVLPX102t && aVLPX084t - aVLPD11Xpp Pediatrics - pregraduation practice
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL101 && aVLIN9X22p && aVLON9X1p && aVLCH9X33c && aVLCH091 && aVLOZ1044 && aVLPD1033c && aVLCJ0888 && (aVLPG1022c ||aVLPG9X1) - aVLPD11XX Pediatrics - state exam
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL7X61c && aVLVL9X62c && aVLVL9X63c && aVLVL9X64c && aVLVL9X65c && aVLVL101 && aVLIN9X22p && aVLCH091 && aVLCH9X33c && aVLON9X1p && aVLOZ1044 && aVLPD1033c && VYCET(1,aVLAL091,aVLDO091,aVLAF091,aVLKB091,aVLFP091,aVLAP111) && aVLCH9X33c && aVLCJ0888 && aVLSP03X && (aVLPG1022c ||aVLPG9X1) && aVLPX102t && aVLPX084t - aVLPG11XX Obstetrics and Gynaecology - State Exam
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL7X61c && aVLVL9X62c && aVLVL9X63c && aVLVL9X64c && aVLVL9X65c && aVLIN9X22p && aVLON9X1p && VYCET(1,aVLAL091,aVLDO091,aVLAF091,aVLKB091,aVLFP091,aVLAP111) && aVLCH9X33c && aVLCJ0888 && aVLSP03X && aVLPG9X1 - aVLPL11Xpp General Medicine Practice and Geriatrics - pregraduation practice
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL101 && aVLIN9X22p && aVLON9X1p && aVLCH9X33c && aVLCH091 && aVLOZ1044 && aVLPD1033c && aVLCJ0888 && (aVLPG1022c ||aVLPG9X1) - aVLPL11XX General Medicine Practice and Geriatrics
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL101 && aVLIN9X22p && aVLON9X1p && aVLCH9X33c && aVLCH091 && aVLOZ1044 && aVLPD1033c && aVLCJ0888 && (aVLPG1022c ||aVLPG9X1) - aVLPP11Xpp Palliative Care - pregraduation practice
aVLFA0822p && aVLNE9X1p && aVLPY9X1p && aVLDV7X1p && aVLAM9X1p && aVLVL101 && aVLIN9X22p && aVLON9X1p && aVLCH9X33c && aVLCH091 && aVLOZ1044 && aVLPD1033c && aVLCJ0888 && (aVLPG1022c ||aVLPG9X1)
- aVLAM9X1p Intensive Care Medicine - lecture
- Teacher's information
General pharmacology:
1. Pharmacology, sub-branches, origin of drugs, drug names2. Types of pharmacotherapy, rules of rational and safe pharmacotherapy. The question of drug misuse.
3. Preclinical and clinical trials, stages.
4. Basic legislation related to drug use, Sources of information on drugs and medicinal products.
5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.
7. Routes of drug administration – overview, characteristics.
8. Drug absorption, presystemic elimination, drug bioavailability.
9. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body.
10. Drug elimination, processes of the first and zero order, drug accumulation.
11. Drug biotransformation – stages, examples.
12. Drug excretion (ways of excretion, possibilities of their influence).
13. Therapeutic monitoring of drugs (TDM).
14. Pharmacokinetics of single, repeated and continual drug administration.
15. Modes of drug action.
16. Inhibition and induction of enzymes in pharmacokinetics and pharmacodynamics of drugs – examples.
17. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics).
18. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence.
19. Adverse drug reactions (types, categories, examples).
20. Pharmacovigilance, drug safety.
21. Influence of repeated administration (tolerance and tachyphylaxis) - examples. Primary resistance of the patient to the treatment.
22. Factors influencing the drug effect – examples.
23. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy.
24. Pharmacotherapy in paediatric population, in breastfeeding women. Drugs influencing breast feeding.
25. Pharmacotherapy in pregnancy, drug teratogenicity.
26. Pharmacogenetics, influence of genetic polymorphisms on pharmacokinetics and pharmacodynamics of drugs.
27. Drug interactions - overview, examples.
28. Principles of biological treatment – classification, technology, examples of clinical use.
Special pharmacology:
1. Sympathomimetics - overview of single classes and their indications, examples of drugs
2. Sympatholytics - overview of single classes and their indications, examples of drugs
3. Cholinomimetics
4. Cholinolytics
5. Antispasmodics - GIT + UGT
6. Opioid analgesics
7. NSAIDs, non-opioid analgesics, antimigraine agents
8. Antiuratics, antirheumatics incl. DMARDs
9. General anesthetics
10. Local anesthetics
11. Muscle relaxants
12. Antidiabetics (except insulins)
13. Insulins
14. . Analogues and antagonists of oestrogenes, gestagenes and androgenes – their basic pharmacology; HRT, hormonal contraception
15. Analogues and antagonists of H-P axis hormones used in pharmacology; uterotonics and tocolytics
16. Glucocorticoids
17. Immunostimulants + immunosuppressants (except glucocorticoids)
18. Drugs used in osteoporosis, pharmacology of thyroid gland
19. Antiasthmatics, drugs used in COPD
20. Antitussives, mucoactive drugs
21. H1 antihistamines
22. Antipsychotics
23. Drugs of neurogenerative diseases (Parkinson’s disease; dementia)
24. Antidepressants - iMAO+SSRI+NDRI
25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS
26. Nootropics, cognitive enhancers
27. Psychostimulants. Drugs used in ADHD. Psychomimetics.
28. Anticonvulsants
29. Hypnosedatives, anxiolytics
30. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC
31. Penicillins, carbapenems
32. Cephalosporines, monobactams
33. Tetracyclines + related ATBs, amphenicoles
34. Macrolides and related ATBs, lincosamides
35. Aminoglycosides, glycopeptides, polymyxins
36. Sulphonamides, nitrofurans and nitroimidazoles
37. Quinolones, antituberculotics
38. Antimycotics
39. Dermatologics – overview of classes, drugs and effects
40. Antivirotics
41. Antiemetic drugs, prokinetics, antivertigo drugs
42. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas
43. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile
44. Drugs for inflammatory bowel disease
45. Alkylating cytostatics and other drugs aiming on DNA in oncology
46. Antimetabolites + hormonal therapy in oncology
47. Targeted treatment in oncology
48. Biological treatment of autoimmune diseases
49. Hypolipidemics, anti-obesity drugs
50. Nitrates and other vasodilators
51. Drugs targeting RAAS
52. Diuretics and aldosterone antagonists
53. Beta blockers + central antihypertensives
54. Calcium channel blockers, α1-lytics
55. Antiarrhythmics
56. Positive inotropic drugs
57. Antiplatelet agents, antianemics
58. Fibrinolytics, antifibrinolytics, hemostatics
59. Anticoagulants
60. Drugs causing addiction and substances used for treatment of addiction
61. General principles of drug poisoning, specific antidotes and their mechanisms of action
62. Drugs used in erectile dysfunction and BHP
63. Antiglaucomatics and cycloplegics
„Essential drugs“
5-fluorouracil • acetylcysteine • acetalsalicylic acid • aciclovir • allopurinol • amiodarone • amlodipine • amphotericin B • aprepitant • atorvastatin • atropine • betahistine • buprenorphine • carbamazepine • caspofungin • cefuroxime • cetirizine • ciclosporine • ciprofloxacin • cisplatin • clarithromycin • clopidogrel • co-amoxicillin • codeine • cotrimoxazole • cyclophosphamide • cyproterone • dabigatran • desflurane • diazepam • digoxin • dobutamine • doxazosin • doxorubicin • doxycycline • empagliflozin • enoxaparin • escitalopram • ethinylestradiol • ezetimibe • famotidine • fenpiverine/pitofenone •fentanyl • finasteride • fluconazole • furosemide • gabapentin • gentamicin • haloperidol • hexoprenaline • ibuprofen • imatinib • indapamide • indometacin • interferons • insulin analogues • ipratropium-bromide • isosorbide dinitrate • ketamine • lactulose • levodopa/carbidopa • levonorgestrel • lidocaine • linagliptin • lithium • loperamide • meropenem • metamizole • metformin • methadone • methotrexate • methyldopa • methylphenidate • metoclopramide • metoprolol • mirtazapine • morphine • naloxone • nimesulide • nivolumab • noradrenaline • olanzapine • ondansetron • oxymetazoline • oxytocin • paclitaxel • pantoprazole • paracetamol • perindopril • phenoxymethylpenicillin • pilocarpine • piperacillin/tazobactam • prednisone • propofol • rivaroxaban • rivastigmine • salbutamol • sildenafil • solifenacin • spironolactone • sumatriptan • suxamethonium • tamoxifen • telmisartan • terbinafine • tramadol • trastuzumab • valproic acid • vancomycin • verapamil • warfarin • zidovudine • zolpidem •
- Enrolment Statistics (spring 2025, recent)
- Permalink: https://is.muni.cz/course/med/spring2025/aVLFA0822p